SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS

• US 20090318456A1
• Filed: 07/06/2007
• Published: 12/24/2009
• Est. Priority Date: 07/06/2006
• Status: Abandoned Application

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: Chong, Lee S., Lee, William A., Bondy, Steven S., De Jonghe, Steven Cesar Alfons, Herdewijn, Piet André Maurits Maria, Watkins, William John
• Application Number:
  US12/307,727
• Publication Number:
  US 20090318456A1
• Time in Patent Office: Days
• US Class Current: 514/249
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: C07D 475/04 with a nitrogen atom directly attached in position 2
• CPC Class Codes: C07D 475/08 with a nitrogen atom directly attached in position 2

Abstract

Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.

Claims

1-33. -33. (canceled)

34. A method of treatment or prevention of an infection due to a virus from the Flaviridae family, consisting essentially of administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative having the structural formula (I):

wherein;

R₁ is selected from the group consisting of hydroxylamino, (mono- or di) C_1-7 alkylamino, (mono- or di) C_1-7 alkyloxyamino, (mono- or di) arylamino, (mono- or di) C_3-10 cycloalkylamino, (mono- or di) hydroxy C_1-7 alkylamino, (mono- or di) C_1-4 alkyl-arylamino, mercapto C_1-7 alkyl, C_1-7 alkyloxy or a saturated or unsaturated heterocyclic compound containing at least one nitrogen and optionally substituted by one or more C_1-4 alkyl, hydroxy C_1-4 alkyl, C_1-4 alkyloxy, halo, hydroxy, hydroxy-carbonyl, and C_1-4 alkyloxycarbonyl;

R₂ is selected from the group consisting of amino, hydroxylamino, (mono- or di) C_1-7 alkylamino, (mono- or di) C_1-7 alkyloxyamino, (mono- or di) arylamino, (mono- or di) C_3-10 cycloalkylamino, (mono- or di) hydroxy C_1-7 alkylamino, (mono- or di) C_1-4 alkyl-arylamino, mercapto C_1-7 alkyl, C_1-7 alkyloxy or a saturated or unsaturated heterocyclic compound containing at least one nitrogen and optionally substituted by one or more C_1-4 alkyl, hydroxy C_1-4 alkyl, C_1-4 alkyloxy, halo, hydroxy, hydroxy-carbonyl, and C_1-4 alkyloxycarbonyl,

R₃ is selected from the group consisting of unsubstituted, monosubstituted and disubstituted aryl groups wherein the optional substituent(s) may be, but are not limited to, halogen, C_1-4 alkoxy, C_1-4 alkyl, aryl groups bonded to the pteridine ring via a saturated or unsaturated aliphatic spacer which may be halogenated or hydroxylated, and aliphatic substituents which may contain an ether, hydroxy, amino or C_1-4 alkoxy group; and

R₄ is selected from the group consisting of hydrogen, alkyl, alkoxy, substituted and non-substituted aryl groups,

and/or a pharmaceutically acceptable addition salt thereof, and/or a stereoisomer thereof, and/or a mono- or a di-N-oxide thereof, and/or a solvate thereof, and/or a dihydro- or tetrahydropteridine derivative thereof, and/or a pro-drug thereof, with the proviso that said pteridine derivative is not 2-amino-4-ethoxy-6-(4-fluorophenyl)-pteridine or 2-amino-4-isopropoxy-6-(4-fluorophenyl)-pteridine.

35. A method according to claim 34, wherein said administration is oral administration.

36. A method according to claim 34, wherein said virus is HCV.

37. A method according to claim 34, wherein said therapeutically effective amount is from 0.1 mg to 5 mg per day per kg bodyweight of said patient.

38. A method of treatment or prevention of an infection due to a virus from the Flaviridae family, consisting essentially of administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative having the structural formula (II)

wherein X represents an oxygen atom or a group with the formula S(O)_m wherein m is an integer from 0 to 2, or a group with the formula NZ and wherein:

R₁ is a group selected from the group consisting of C_1-7 alkyl, C_2-7 alkenyl, C_2-7 alkynyl, C_3-10 cycloalkyl, C_3-10 cycloalkenyl, aryl, alkylaryl, arylalkyl, heterocyclic, heterocyclic-substituted alkyl and alkyl-substituted heterocyclic, each of said groups being optionally substituted with one or more substituents selected from the group consisting of halogen, C_1-4 alkyl and C_1-4 alkoxy;

or R₁ is a carboxyalkyl, carboxyaryl, thiocarboxyaryl or thiocarboxyalkyl group;

Z is a group independently defined as R₁ or Z is hydrogen or the group NZ together with R₁ is either hydroxylamino or an optionally substituted heterocyclic group containing at least one nitrogen atom;

R₂ is selected from the group consisting of amino;

acylamino;

thioacylamino;

carbamoyl;

thiocarbamoyl, ureido;

thio-ureido, sulfonamido;

hydroxylamino;

alkoxyamino;

thioalkylamino;

mercaptoamino, hydrazino;

alkylhydrazino;

phenylhydrazino;

optionally substituted heterocyclic radicals;

C_3-7 alkylamino;

arylamino;

arylalkylamino;

cycloalkylamino;

alkenylamino;

cycloalkenylamino;

heterocyclic amino;

hydroxyalkylamino;

mercaptoalkylamino;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

thio C_1-7 alkyl;

arylsulfoxide;

arylsulfone;

heterocyclic sulfoxide;

heterocyclic sulfone;

thio C_3-10 cycloalkyl;

aryloxy;

arylthio;

arylalkyloxy;

arylalkylthio;

oxyheterocyclic and thioheterocyclic radicals;

R₄ is an atom or a group selected from the group consisting of hydrogen;

halogen;

C_1-7 alkyl;

C_2-7 alkenyl;

C_2-7 alkynyl;

halo C_1-7 alkyl;

carboxy C_1-7 alkyl;

carboxyaryl;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

aryloxy;

arylalkyloxy;

oxyheterocyclic;

heterocyclic-substituted alkyloxy;

thio C_1-7 alkyl;

thio C_3-10 cycloalkyl;

thioaryl;

thioheterocyclic;

arylalkylthio;

heterocyclic-substituted alkylthio;

hydroxylamino;

mercapto-amino;

acylamino;

thio-acylamino;

alkoxyamino;

thioalkylamino;

acetal;

thio-acetal;

carboxylic acid;

carboxylic acid esters, thioesters, halides, anhydrides, amides and thioamides;

thiocarboxylic acid;

thiocarboxylic acid esters, thioesters, halides, anhydrides, amides and thioamides;

hydroxyl;

sulfhydryl;

nitro;

cyano;

carbamoyl;

thiocarbamoyl, ureido;

thio-ureido;

alkylamino;

cycloalkylamino;

alkenylamino;

cycloalkenyl-amino;

alkynylamino;

arylamino;

arylalkylamino;

hydroxyalkylamino;

mercaptoalkylamino;

heterocyclic amino;

heterocyclic-substituted alkylamino;

oximino;

alkyloximino;

hydrazino;

alkylhydrazino;

phenylhydrazino;

cysteinyl acid, esters, thioesters, halides, anhydrides, amides and thioamides thereof;

phenyl substituted with one or more substituents selected from the group consisting of C_1-7 alkyl, C_2-7 alkenyl, C_2-7 alkynyl, halo C_1-7 alkyl, nitro, hydroxyl, sulfhydryl, amino, C_3-10 cycloalkoxy, aryloxy, arylalkyloxy, oxyheterocyclic, heterocyclic-substituted alkyloxy, thio C_1-7 alkyl, thio C_3-10 cycloalkyl, thioaryl, thioheterocyclic, arylalkylthio, heterocyclic-substituted alkylthio, formyl, carbamoyl, thiocarbamoyl, ureido, thio-ureido, sulfonamido, hydroxylamino, alkoxyamino, mercaptoamino, thioalkylamino, acylamino, thioacylamino, cyano, carboxylic acid or esters or thioesters or halides or anhydrides or amides thereof, thiocarboxylic acid or esters or thioesters or halides or anhydrides or amides thereof, alkylamino, cycloalkylamino, alkenylamino, cycloalkenylamino, alkynyl-amino, arylamino, arylalkylamino, hydroxyalkylamino, mercaptoalkylamino, heterocyclic amino, hydrazino, alkylhydrazino and phenylhydrazino;

aryl groups other than phenyl, the said aryl groups being optionally substituted with one or more substituents selected from the group consisting of halogen, C_1-7 alkyl, C_1-7 alkoxy;

optionally substituted heterocyclic radicals;

aromatic or heterocyclic substituents substituted with an aliphatic spacer between the pteridine ring and the aromatic or heterocyclic substituent, whereby said aliphatic spacer is a branched or straight, saturated or unsaturated aliphatic chain of 1 to 4 carbon atoms which may contain one or more functions, atoms or radicals selected from the group consisting of carbonyl (oxo), thiocarbonyl, alcohol (hydroxyl), thiol, ether, thio-ether, acetal, thio-acetal, amino, imino, oximino, alkyloximino, amino-acid, cyano, sulfonyl, sulfinyl, sulfonamido and halogen;

branched or straight, saturated or unsaturated aliphatic chains of 1 to 7 carbon atoms optionally containing one or more functions selected from the group consisting of carbonyl (oxo), thiocarbonyl, alcohol (hydroxyl), thiol, ether, thio-ether, acetal, thio-acetal, amino, imino, oximino, alkyloximino, aminoacid, cyano, sulfonyl, sulfinyl, sulfonamido and halogen; and

R₃ is an atom or a group selected from the group consisting of fluoro, bromo, iodo, C_2-7 alkyl;

C_2-7 alkenyl;

C_2-7 alkynyl;

halo C_1-7 alkyl;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

aryloxy;

arylalkyloxy;

oxyheterocyclic;

heterocyclic-substituted alkyloxy;

thio C_2-7 alkyl;

thio C_3-10 cycloalkyl;

thioaryl;

thioheterocyclic;

arylalkylthio;

heterocyclic-substituted alkylthio;

hydroxylamino;

alkoxyamino;

thioalkylamino;

mercaptoamino;

acylamino;

thio-acylamino;

thio-acetal;

carboxylic acid;

carboxylic acid esters, thioesters, amides, halides, anhydrides and thioamides;

thiocarboxylic acid;

thiocarboxylic acid esters, thioesters, amides, halides, anhydrides and thioamides;

hydroxyl;

sulfhydryl;

nitro;

carbamoyl;

thiocarbamoyl;

ureido;

thio-ureido;

amino;

alkylamino;

cycloalkylamino;

alkenylamino;

cycloalkenylamino;

alkynylamino;

arylamino;

arylalkylamino;

hydroxyalkyl-amino;

mercaptoalkylamino;

heterocyclic amino;

heterocyclic-substituted alkylamino;

oximino;

alkyloximino;

hydrazino;

alkylhydrazino;

phenyl-hydrazino;

cysteinyl acid, esters, thioesters, amides and thioamides thereof;

aryl optionally substituted with one or more substituents selected from the group consisting of halogen, C_1-7 alkyl and C_1-7 alkoxy;

optionally substituted heterocyclic radicals;

aromatic or heterocyclic substituents substituted with an aliphatic spacer between the pteridine ring and the aromatic or heterocyclic substituent, whereby said aliphatic spacer is a branched or straight, saturated or unsaturated aliphatic chain of 1 to 4 carbon atoms which may contain one or more functions, atoms or radicals selected from the group consisting of carbonyl (oxo), thiocarbonyl, alcohol (hydroxyl), thiol, ether, thio-ether, acetal, thio-acetal, amino, imino, oximino, alkyloximino, amino-acid, cyano, carboxylic acid or ester or thioester or amide, nitro, thio C_1-7 alkyl, thio C_3-10 cycloalkyl, alkylamino, sulfonyl, sulfonamido and halogen;

branched or straight, saturated or unsaturated aliphatic chains of 2 to 7 carbon atoms optionally containing one or more functions selected from the group consisting of thiocarbonyl, alcohol (hydroxyl), thiol, ether, thio-ether, thio-acetal, amino, imino, oximino, alkyloximino, amino-acid, cyano, sulfonyl, sulfinyl, sulfonamido and halogen;

or R₃ together with R₄ forms a homocyclic or heterocyclic radical;

and/or a pharmaceutically acceptable addition salt thereof, and/or a stereoisomer thereof, and/or a mono- or a di-N-oxide thereof, and/or a solvate thereof, and/or a dihydro- or tetrahydropteridine derivative thereof, and/or a pro-drug thereof, with the proviso that said pteridine derivative is not 2-amino-4-ethoxy-6-(4-fluorophenyl)-pteridine or 2-amino-4-isopropoxy-6-(4-fluorophenyl)-pteridine.

39. A method according to claim 38, wherein said virus is HCV.

40. A method according to claim 38, wherein said therapeutically effective amount is from 0.1 mg to 5 mg per day per kg bodyweight of said patient.

41. A method according to claim 38, wherein said administration is oral administration.

42. A method of treatment or prevention of an infection due to a virus from the Flaviridae family, consisting essentially of administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative having the structural formula (III):

wherein;

a first group of one or more of the substituents R₂, R₃, R₄ and R₅ of the pteridine ring is independently selected from groups represented by the general formula (IV);

wherein;

schematically represents a saturated or partly unsaturated heterocyclic ring with at least two nitrogen atoms in the said heterocyclic ring and with a total of 5 to 7 atoms in the said heterocyclic ring, and optionally with one or more other heteroatoms (e.g. oxygen or sulfur) in the said heterocyclic ring or attached to one or more carbon atoms of said heterocyclic ring (for instance in the form of a carbonyl or thiocarbonyl group), wherein one of said at least two nitrogen atoms in the heterocyclic ring is attached to a carbon atom of the pteridine ring at any of positions 2, 4, 6 or 7 of the pteridine ring, wherein the said heterocyclic ring may be fused to one or more aromatic hydrocarbon rings, and wherein;

each substituent R₀ of the heterocyclic ring (III) is a group independently selected from the group consisting of halogen and C_1-7 alkyl;

n is an integer from 0 to 6;

R₁ is a substituent group selected from the group consisting of formyl, acyl, thio-acyl, amide, thioamide, sulfonyl, sulfinyl, carboxylate, thiocarboxylate, amino-substituted acyl, alkoxyalkyl, C_3-10 cycloalkyl-alkyl, C_3-10 cyclo-alkyl, dialkylaminoalkyl, heterocyclic-substituted alkyl, acyl-substituted alkyl, thioacyl-substituted alkyl, amido-substituted alkyl, thioamido-substituted alkyl, carboxylato-substituted alkyl, thiocarboxylato-substituted alkyl, (amino-substituted acyl)alkyl, heterocyclic, carboxylic acid ester, ω

-cyanoalkyl, ω

-carboxylic ester-alkyl, halo C_1-7 alkyl, C_2-7 alkenyl, C_2-7 alkynyl, arylalkenyl, aryloxyalkyl, arylalkyl and aryl, wherein the aryl moiety of each of said arylalkenyl, aryloxyalkyl, arylalkyl and aryl radicals is optionally substituted with one or more substituents; and

wherein a second group of the substituents R₂, R₃, R₄ and R₅ of the pteridine ring is independently selected from the group consisting of hydrogen;

halogen;

C_1-7 alkyl;

C_2-7 alkenyl;

C_2-7 alkynyl;

halo C_1-7 alkyl;

carboxy C_1-7 alkyl;

carboxyaryl;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

aryloxy;

arylalkyloxy;

oxyheterocyclic;

heterocyclic-substituted alkyloxy;

thio C_1-7 alkyl;

thio C_3-10 cycloalkyl;

thioaryl;

thioheterocyclic;

arylalkylthio;

heterocyclic-substituted alkylthio;

hydroxylamino;

mercapto-amino;

acylamino;

thio-acylamino;

alkoxyamino;

thioalkylamino;

amino;

alkylamino;

cycloalkylamino;

arylamino;

arylalkylamino;

hydroxyalkylamino;

mercaptoalkylamino;

heterocyclic-substituted amino;

heterocyclic-substituted arylamino;

heterocyclic-substituted alkylamino;

aryl optionally substituted with one or more substituents;

optionally substituted heterocyclic radicals;

aromatic or heterocyclic substituents substituted with an aliphatic spacer between the pteridine ring and the aromatic or heterocyclic substituent, whereby said aliphatic spacer is a branched or straight, saturated or unsaturated aliphatic chain of 1 to 4 carbon atoms which may contain one or more functions, atoms or radicals independently selected from the group consisting of carbonyl, thiocarbonyl, hydroxyl, thiol, ether and halogen;

branched or straight, saturated or unsaturated aliphatic chains of 1 to 7 carbon atoms optionally containing one or more functions, atoms or radicals independently selected from the group consisting of halogen, carbonyl, thiocarbonyl, hydroxyl, thiol, ether and amino;

or R₂ together with R₃ and the carbon atoms in positions 6 and 7 of the pteridine ring forms a homocyclic or heterocyclic radical;

and/or a pharmaceutically acceptable addition salt thereof, and/or a stereoisomer thereof, and/or a mono- or a di-N-oxide thereof, and/or a solvate thereof, and/or a dihydro- or tetrahydropteridine derivative thereof, and/or a pro-drug thereof.

43. A method according to claim 42, wherein said virus is HCV.

44. A method according to claim 42, wherein said therapeutically effective amount is from 0.1 mg to 5 mg per day per kg bodyweight of said patient.

45. A method according to claim 42, wherein said administration is oral administration.

46. A pteridine derivative represented by

the structural formula (VI):

or the structural formula (VIII)

wherein;

R₁ is selected from the group consisting of hydroxylamino, (mono- or di) C_1-7 alkylamino, (mono- or di) C_1-7 alkyloxyamino, (mono- or di) arylamino, (mono- or di) C_3-10 cycloalkylamino, (mono- or di) hydroxy C_1-7 alkylamino, (mono- or di) C_1-4 alkyl-arylamino, mercapto C_1-7 alkyl, C_1-7 alkyloxy or a saturated or unsaturated heterocyclic compound containing at least one nitrogen and optionally substituted by one or more C_1-4 alkyl, hydroxy C_1-4 alkyl, C_1-4 alkyloxy, halo, hydroxy, hydroxy-carbonyl, and C_1-4 alkyloxycarbonyl;

R₃ is selected from the group consisting of unsubstituted, monosubstituted and disubstituted aryl groups wherein the optional substituent(s) may be, but are not limited to, halogen, C_1-4 alkoxy, C_1-4 alkyl, aryl groups bonded to the pteridine ring via a saturated or unsaturated aliphatic spacer which may be halogenated or hydroxylated, and aliphatic substituents which may contain an ether, hydroxy, amino or C_1-4 alkoxy group; and

R₄ is selected from the group consisting of hydrogen, alkyl, alkoxy, substituted and non-substituted aryl groups,

R₂′

is —

NH—

CHR₆R₇ or —

NH—

R₈, wherein R₆ and R₇ are independently selected from the group consisting of hydrogen, C_1-6 alkyl substituted with one or more substituents selected from the group consisting of halogen and C_1-4 alkoxy, C_3-10 cycloalkyl, aryl and heterocyclyl, wherein said aryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_1-4 alkyl, C_1-4 alkoxy, di-C_1-4 alkylamino, mono-C_1-4 alkylamino, carboxamido, sulfamoyl, carbamoyl, sulfonamido and phenoxy, provided that R₆ and R₇ are not both hydrogen; and

wherein R₈ is selected from the group consisting of C_3-10 cycloalkyl substituted at the carbon position adjacent to the N atom of R₂′

with aryl or heteroaryl wherein said aryl is optionally substituted with halogen, heteroaryl, and heteroaryl or aryl wherein said heteroaryl or aryl is substituted with one or more substituents selected from the group consisting of halogen and C_1-4 alkyl;

R₃′

is selected from the group consisting of halogen, heterocyclyl, and, mono-substituted or disubstituted aryl and heterocyclyl, wherein at least one substituent of said aryl is selected from the group consisting of amino, C_4-6 alkyl, C_4-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy, and optionally further substituted with halogen, C_1-4 alkyl, C_1-4 alkoxy; and

at least one substituent of said heterocyclyl is selected from the group consisting of halogen, amino, C_1-6 alkyl, C_1-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy;

R₉ is selected from the group consisting of H, C_3-10 cycloalkyl optionally substituted with one more substituents selected from the group consisting of cyano, halogen, hydroxy, amino, C_1-6 alkyl and C_1-6 alkoxy;

C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

C_1-6 alkoxy;

heterocyclyl optionally substituted with C_1-6 alkyl; and

phenyl optionally substituted with one or more halogens;

R₁₀ and R₁₁ are each independently selected from the group consisting of C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, cyano, halogen and hydroxy;

C_1-6 alkoxy optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

heterocyclyl optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl, acylamino and oxo;

C_3-10 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of amino or hydroxy; and

amino optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen and heterocyclyl;

R₁₂ is selected from the group consisting of H and C_1-6 alkyl, wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of cyano, halogen and hydroxy;

or a pharmaceutical acceptable addition salt or a stereochemical isomeric form thereof or a N-oxide thereof or a solvate thereof or a prodrug thereof.

49. A pharmaceutical composition comprising at least one pteridine derivative according to claim 46.

52. A method of treatment or prevention of an infection due to a virus from the Flaviviridae family, by administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative according to claim 46.

47. A pteridine derivative represented by

or the structural formula (X)

or the structural formula (XI)

wherein X represents an oxygen atom or a group with the formula S(O)_m wherein m is an integer from 0 to 2, or a group with the formula NZ and wherein:

R₁ is a group selected from the group consisting of C_1-7 alkyl, C_2-7 alkenyl, C_2-7 alkynyl, C_3-10 cycloalkyl, C_3-10 cycloalkenyl, aryl, alkylaryl, arylalkyl, heterocyclic, heterocyclic-substituted alkyl and alkyl-substituted heterocyclic, each of said groups being optionally substituted with one or more substituents selected from the group consisting of halogen, C_1-4 alkyl and C_1-4 alkoxy;

or R₁ is a carboxyalkyl, carboxyaryl, thiocarboxyaryl or thiocarboxyalkyl group;

Z is a group independently defined as R₁ or Z is hydrogen or the group NZ together with R₁ is either hydroxylamino or an optionally substituted heterocyclic group containing at least one nitrogen atom;

R₄ is an atom or a group selected from the group consisting of hydrogen;

halogen;

C_1-7 alkyl;

C_2-7 alkenyl;

C_2-7 alkynyl;

halo C_1-7 alkyl;

carboxy C_1-7 alkyl;

carboxyaryl;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

aryloxy;

arylalkyloxy;

thio C_1-7 alkyl;

thio C_3-10 cycloalkyl;

thioaryl;

arylalkylthio;

acetal;

thio-acetal;

carboxylic acid;

carboxylic acid esters, thioesters, halides, anhydrides, amides and thioamides;

thiocarboxylic acid;

thiocarboxylic acid esters, thioesters, halides, anhydrides, amides and thioamides;

hydroxyl;

sulfhydryl;

nitro;

cyano;

carbamoyl;

thiocarbamoyl, ureido;

thio-ureido;

hydrazino;

alkylhydrazino;

phenylhydrazino;

cysteinyl acid, esters, thioesters, halides, anhydrides, amides and thioamides thereof;

phenyl substituted with one or more substituents selected from the group consisting of C_1-7 alkyl, C_2-7 alkenyl, C_2-7 alkynyl, halo C_1-7 alkyl, nitro, hydroxyl, sulfhydryl, amino, C_3-10 cycloalkoxy, aryloxy, arylalkyloxy, thio C_1-7 alkyl, thio C_3-10 cycloalkyl, thioaryl, thioheterocyclic, arylalkylthio, formyl, carbamoyl, thiocarbamoyl, ureido, thio-ureido, sulfonamido, cyano, carboxylic acid or esters or thioesters or halides or anhydrides or amides thereof, thiocarboxylic acid or esters or thioesters or halides or anhydrides or amides thereof, hydrazino, alkylhydrazino and phenylhydrazino;

aryl groups other than phenyl, the said aryl groups being optionally substituted with one or more substituents selected from the group consisting of halogen, C_1-7 alkyl, C_1-7 alkoxy; and

R₃ is an atom or a group selected from the group consisting of fluoro, bromo, iodo, C_2-7 alkyl;

C_2-7 alkenyl;

C_2-7 alkynyl;

halo C_1-7 alkyl;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

aryloxy;

arylalkyloxy;

oxyheterocyclic;

heterocyclic-substituted alkyloxy;

thio C_2-7 alkyl;

thio C_3-10 cycloalkyl;

thioaryl;

thioheterocyclic;

arylalkylthio;

heterocyclic-substituted alkylthio;

hydroxylamino;

alkoxyamino;

thioalkylamino;

mercaptoamino;

acylamino;

thio-acylamino;

thio-acetal;

carboxylic acid;

carboxylic acid esters, thioesters, amides, halides, anhydrides and thioamides;

thiocarboxylic acid;

thiocarboxylic acid esters, thioesters, amides, halides, anhydrides and thioamides;

hydroxyl;

sulfhydryl;

nitro;

carbamoyl;

thiocarbamoyl;

ureido;

thio-ureido;

amino;

alkylamino;

cycloalkylamino;

alkenylamino;

cycloalkenylamino;

alkynylamino;

arylamino;

arylalkylamino;

hydroxyalkyl-amino;

mercaptoalkylamino;

heterocyclic amino;

heterocyclic-substituted alkylamino;

oximino;

alkyloximino;

hydrazino;

alkylhydrazino;

phenyl-hydrazino;

cysteinyl acid, esters, thioesters, amides and thioamides thereof;

aryl optionally substituted with one or more substituents selected from the group consisting of halogen, C_1-7 alkyl and C_1-7 alkoxy;

optionally substituted heterocyclic radicals;

aromatic or heterocyclic substituents substituted with an aliphatic spacer between the pteridine ring and the aromatic or heterocyclic substituent, whereby said aliphatic spacer is a branched or straight, saturated or unsaturated aliphatic chain of 1 to 4 carbon atoms which may contain one or more functions, atoms or radicals selected from the group consisting of carbonyl (oxo), thiocarbonyl, alcohol (hydroxyl), thiol, ether, thio-ether, acetal, thio-acetal, amino, imino, oximino, alkyloximino, amino-acid, cyano, carboxylic acid or ester or thioester or amide, nitro, thio C_1-7 alkyl, thio C_3-10 cycloalkyl, alkylamino, sulfonyl, sulfonamido and halogen;

branched or straight, saturated or unsaturated aliphatic chains of 2 to 7 carbon atoms optionally containing one or more functions selected from the group consisting of thiocarbonyl, alcohol (hydroxyl), thiol, ether, thio-ether, thio-acetal, amino, imino, oximino, alkyloximino, amino-acid, cyano, sulfonyl, sulfinyl, sulfonamido and halogen;

or R₃ together with R₄ forms a homocyclic or heterocyclic radical;

R₂′

is —

NH—

CHR₆R₇ or —

NH—

R₈, wherein R₆ and R₇ are independently selected from the group consisting of hydrogen, C_1-6 alkyl substituted with one or more substituents selected from the group consisting of halogen and C_1-4 alkoxy, C_3-10 cycloalkyl, heterocyclyl, and aryl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_1-4 alkyl, C_1-4 alkoxy, di-C_1-4 alkylamino, mono-C_1-4 alkylamino, carboxamido, sulfamoyl, carbamoyl, sulfonamido and phenoxy, provided that R₆ and R₇ are not both hydrogen; and

wherein R₈ is selected from the group consisting of C_3-10 cycloalkyl optionally substituted at the carbon position adjacent to the N atom of R₂′

with aryl or heteroaryl wherein said aryl is optionally substituted with halogen, heteroaryl, and heteroaryl or aryl wherein said heteroaryl or aryl is substituted with one or more substituents selected from the group consisting of halogen and C_1-4 alkyl;

R₃′

is selected from the group consisting of halogen, heterocyclyl, and, mono-substituted or disubstituted aryl and heterocyclyl, wherein at least one substituent of said aryl is selected from the group consisting of amino, C_4-6 alkyl, C_4-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy, and optionally further substituted with halogen, C_1-4 alkyl, C_1-4 alkoxy; and

at least one substituent of said heterocyclyl is selected from the group consisting of halogen, amino, C_1-6 alkyl, C_1-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy;

R₉ is selected from the group consisting of H, C_3-10 cycloalkyl optionally substituted with one more substituents selected from the group consisting of cyano, halogen, hydroxy, amino, C_1-6 alkyl and C_1-6 alkoxy;

C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

C_1-6 alkoxy;

heterocyclyl optionally substituted with C_1-6 alkyl; and

phenyl optionally substituted with one or more halogens;

R₁₀ and R₁₁ are each independently selected from the group consisting of C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, cyano, halogen and hydroxy;

C_1-6 alkoxy optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

heterocyclyl optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl, acylamino and oxo;

C_3-10 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of amino or hydroxy; and

amino optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen and heterocyclyl;

R₁₂ is selected from the group consisting of H and C_1-6 alkyl, wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of cyano, halogen and hydroxy;

or a pharmaceutical acceptable addition salt or a stereochemical isomeric form thereof or a N-oxide thereof or a solvate thereof or a prodrug thereof.

50. A pharmaceutical composition comprising at least one pteridine derivative according to claim 47.

53. A method of treatment or prevention of an infection due to a virus from the Flaviviridae family, by administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative according to claim 47.

48. A pteridine derivative represented by

or the structural formula (XIII)

or the structural formula (XIV)

wherein

a first group of one or more of the substituents R₂, R₃ and R₅ of the pteridine ring is independently selected from groups represented by the general formula (IV):

wherein;

schematically represents a saturated or partly unsaturated heterocyclic ring with at least two nitrogen atoms in the said heterocyclic ring and with a total of 5 to 7 atoms in the said heterocyclic ring, and optionally with one or more other heteroatoms (e.g. oxygen or sulfur) in the said heterocyclic ring or attached to one or more carbon atoms of said heterocyclic ring (for instance in the form of a carbonyl or thiocarbonyl group), wherein one of said at least two nitrogen atoms in the heterocyclic ring is attached to a carbon atom of the pteridine ring at any of positions 2, 4, 6 or 7 of the pteridine ring, wherein the said heterocyclic ring may be fused to one or more aromatic hydrocarbon rings, and wherein;

each substituent R₀ of the heterocyclic ring (III) is a group independently selected from the group consisting of halogen and C_1-7 alkyl;

n is an integer from 0 to 6;

R₁ is a substituent group selected from the group consisting of formyl, acyl, thio-acyl, amide, thioamide, sulfonyl, sulfinyl, carboxylate, thiocarboxylate, amino-substituted acyl, alkoxyalkyl, C_3-10 cycloalkyl-alkyl, C_3-10 cyclo-alkyl, dialkylaminoalkyl, heterocyclic-substituted alkyl, acyl-substituted alkyl, thioacyl-substituted alkyl, amido-substituted alkyl, thioamido-substituted alkyl, carboxylato-substituted alkyl, thiocarboxylato-substituted alkyl, (amino-substituted acyl)alkyl, heterocyclic, carboxylic acid ester, ω

-cyanoalkyl, ω

-carboxylic ester-alkyl, halo C_1-7 alkyl, C_2-7 alkenyl, C_2-7 alkynyl, arylalkenyl, aryloxyalkyl, arylalkyl and aryl, wherein the aryl moiety of each of said arylalkenyl, aryloxyalkyl, arylalkyl and aryl radicals is optionally substituted with one or more substituents; and

wherein a second group of the substituents R₂, R₃ and R₅ of the pteridine ring is independently selected from the group consisting of hydrogen;

halogen;

C_1-7 alkyl;

C_2-7 alkenyl;

C_2-7 alkynyl;

halo C_1-7 alkyl;

carboxy C_1-7 alkyl;

carboxyaryl;

C_1-7 alkoxy;

C_3-10 cycloalkoxy;

aryloxy;

arylalkyloxy;

thio C_1-7 alkyl;

thio C_3-10 cycloalkyl;

thioaryl;

arylalkylthio;

hydroxylamino;

mercapto-amino;

acylamino;

thio-acylamino;

alkoxyamino;

thioalkylamino;

amino;

alkylamino;

cycloalkylamino;

arylamino;

arylalkylamino;

hydroxyalkylamino;

mercaptoalkylamino;

aryl optionally substituted with one or more substituents;

aromatic or heterocyclic substituents substituted with an aliphatic spacer between the pteridine ring and the aromatic or heterocyclic substituent, whereby said aliphatic spacer is a branched or straight, saturated or unsaturated aliphatic chain of 1 to 4 carbon atoms which may contain one or more functions, atoms or radicals independently selected from the group consisting of carbonyl, thiocarbonyl, hydroxyl, thiol, ether and halogen;

branched or straight, saturated or unsaturated aliphatic chains of 1 to 7 carbon atoms optionally containing one or more functions, atoms or radicals independently selected from the group consisting of halogen, carbonyl, thiocarbonyl, hydroxyl, thiol, ether and amino;

or R₂ together with R₃ and the carbon atoms in positions 6 and 7 of the pteridine ring forms a homocyclic or heterocyclic radical;

and wherein

R₄′

is —

NH—

CHR₆R₇ or —

NH—

R₈, wherein R₆ and R₇ are independently selected from the group consisting of hydrogen, C_1-6 alkyl substituted with one or more substituents selected from the group consisting of halogen and C_1-4 alkoxy, C_3-10 cycloalkyl, heterocyclyl, and aryl substituted with one or more substituents selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, trifluoromethyl, trifluoromethoxy, C_1-4 alkyl, C_1-4 alkoxy, di-C_1-4 alkylamino, mono-C_1-4 alkylamino, carboxamido, sulfamoyl, carbamoyl, sulfonamido and phenoxy, provided that R₆ and R₇ are not both hydrogen; and

wherein R₈ is selected from the group consisting of C_3-10 cycloalkyl optionally substituted at the carbon position adjacent to the N atom of R₄′

with aryl or heteroaryl wherein said aryl is optionally substituted with halogen, heteroaryl, and heteroaryl or aryl wherein said heteroaryl or aryl is substituted with one or more substituents selected from the group consisting of halogen and C_1-4 alkyl;

R₂′

is selected from the group consisting of halogen, heterocyclyl, and, mono-substituted or disubstituted aryl and heterocyclyl, wherein at least one substituent of said aryl or heterocyclyl is selected from the group consisting of halogen, amino, C_1-6 alkyl, C_1-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy;

R₉ is selected from the group consisting of H, C_3-10 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of cyano, halogen, hydroxy, amino, C_1-6 alkyl and C_1-6 alkoxy;

C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

C_1-6 alkoxy;

heterocyclyl optionally substituted with C_1-6 alkyl; and

phenyl optionally substituted with one or more halogens;

R₁₀ and R₁₁ are each independently selected from the group consisting of C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, cyano, halogen and hydroxy;

C_1-6 alkoxy optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

heterocyclyl optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl, acylamino and oxo;

C_3-10 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of amino or hydroxy; and

amino optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen and heterocyclyl;

R₁₂ is selected from the group consisting of H and C_1-6 alkyl, wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of cyano, halogen and hydroxy;

or a pharmaceutical acceptable addition salt or a stereochemical isomeric form thereof or a N-oxide thereof or a solvate thereof or a prodrug thereof.

51. A pharmaceutical composition comprising at least one pteridine derivative according to claim 48.

54. A method of treatment or prevention of an infection due to a virus from the Flaviviridae family, by administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative according to claim 48.

59. A method according to claim 54, wherein said therapeutically effective amount is from 0.1 mg to 5 mg per day per kg bodyweight of said patient.

55. A method of treatment or prevention of an infection due to a virus from the Flaviviridae family, by administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative according to

the structural formula (VII)

wherein:

R₁ is selected from the group consisting of hydroxylamino, (mono- or di) C_1-7 alkylamino, (mono- or di) C_1-7 alkyloxyamino, (mono- or di) arylamino, (mono- or di) C_3-10 cycloalkylamino, (mono- or di) hydroxy C_1-7 alkylamino, (mono- or di) C_1-4 alkyl-arylamino, mercapto C_1-7 alkyl, C_1-7 alkyloxy or a saturated or unsaturated heterocyclic compound containing at least one nitrogen and optionally substituted by one or more C_1-4 alkyl, hydroxy C_1-4 alkyl, C_1-4 alkyloxy, halo, hydroxy, hydroxy-carbonyl, and C_1-4 alkyloxycarbonyl;

R₂ is selected from the group consisting of amino, hydroxylamino, (mono- or di) C_1-7 alkylamino, (mono- or di) C_1-7 alkyloxyamino, (mono- or di) arylamino, (mono- or di) C_3-10 cycloalkylamino, (mono- or di) hydroxy C_1-7 alkylamino, (mono- or di) C_1-4 alkyl-arylamino, mercapto C_1-7 alkyl, C_1-7 alkyloxy or a saturated or unsaturated heterocyclic compound containing at least one nitrogen and optionally substituted by one or more C_1-4 alkyl, hydroxy C_1-4 alkyl, C_1-4 alkyloxy, halo, hydroxy, hydroxy-carbonyl, and C_1-4 alkyloxycarbonyl,

R₄ is selected from the group consisting of hydrogen, alkyl, alkoxy, substituted and non-substituted aryl groups,

R₃′

is selected from the group consisting of halogen, heterocyclyl, and, mono-substituted or disubstituted aryl and heterocyclyl, wherein at least one substituent of said aryl is selected from the group consisting of amino, C_4-6 alkyl, C_4-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy, and optionally further substituted with halogen, C_1-4 alkyl, C_1-4 alkoxy; and

at least one substituent of said heterocyclyl is selected from the group consisting of halogen, amino, C_1-6 alkyl, C_1-6 alkoxy, —

CONHR₉, —

NR₁₂COR₁₀, —

NR₁₂SO₂R₁₁, —

SO₂NH₂, heterocyclyl and heterocyclyl substituted with one or more substituents selected from the group consisting of hydroxy, oxo, halogen, amino, C_1-6 alkyl and C_1-6 alkoxy;

R₉ is selected from the group consisting of H, C_3-10 cycloalkyl optionally substituted with one more substituents selected from the group consisting of cyano, halogen, hydroxy, amino, C_1-6 alkyl and C_1-6 alkoxy;

C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

C_1-6 alkoxy;

heterocyclyl optionally substituted with C_1-6 alkyl; and

phenyl optionally substituted with one or more halogens;

R₁₀ and R₁₁, are each independently selected from the group consisting of C_1-6 alkyl optionally substituted with one or more substituents selected from the group consisting of amino, cyano, halogen and hydroxy;

C_1-6 alkoxy optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen, and heterocyclyl;

heterocyclyl optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl, acylamino and oxo;

C_3-10 cycloalkyl optionally substituted with one or more substituents selected from the group consisting of amino or hydroxy; and

amino optionally substituted with one or more substituents selected from the group consisting of C_1-6 alkyl wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of amino, alkylamino, cyano, dialkylamino, halogen and heterocyclyl;

R₁₂ is selected from the group consisting of H and C_1-6 alkyl, wherein said C_1-6 alkyl is optionally substituted with one or more substituents selected from the group consisting of cyano, halogen and hydroxy;

or a pharmaceutical acceptable addition salt or a stereochemical isomeric form thereof or a N-oxide thereof or a solvate thereof or a prodrug thereof.

56. A method according to claim 55, wherein said administration is oral.

57. A method according to claim 55, wherein said virus is HCV.

58. A method according to claim 55, wherein said therapeutically effective amount is from 0.1 mg to 5 mg per day per kg bodyweight of said patient.

60. A pteridine derivative selected from the group consisting of:

4-ethoxy-6-(4-acetamidophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-acetamidophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-acetylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-acetylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-acetylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(5-acetyl-2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-acetyl-3-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(5-acetyl-2-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-aminophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-aminomethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-benzyloxy-2-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-benzyloxy-3-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-bromophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-bromophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-bromo-2,5-dimethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-bromo-5-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-bromo-6-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-carboxy-5-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-carboxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-carboxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-carboxy-2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(5-carboxy-2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-carboxy-3-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-carboxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-5-formylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-5-hydroxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-chloro-4-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-4-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-chloro-2-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-chloro-5-methoxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-4-methylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-5-methylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-chloro-5-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-5-trifluoromethoxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-chloro-2-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-cyanophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-cyanophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-cyanophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,6-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3,4-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,6-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,4-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,3-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3,5-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3,5-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3,4-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,6-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,5-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,4-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,3-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-[N,N-dimethylamino]phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-[N,N-dimethylaminomethyl]phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3,5-dimethyl phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3,4-dimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2,6-dimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2,6-dimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2,5-dimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2,4-dimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-ethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-ethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-ethoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-ethoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-ethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-fluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-fluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-fluoro-4-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-fluoro-3-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-fluoro-2-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-fluoro-5-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-fluoro-5-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-fluoro-2-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-formyl-5-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-formyl-2-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-formyl-5-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-hydroxy-4-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-hydroxymethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-hydroxymethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-hydroxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-hydroxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-iodophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-iodophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-isopropoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-isopropoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-methanesulfonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-methoxy-2-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3,4-methylenedioxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-(methylthio)phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-(methylthio)phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-morpholinophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-nitrophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-phenoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-(tert-butoxycarbonyl)phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3-(tert-butoxycarbonyl)phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-(tert-butoxycarbonyl)phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(4-(tert-butoxycarbonylamino)-3-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-(tert-butylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-(2-thienyl)phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-trifluoromethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2,4,6-trimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3,4,5-trifluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-trifluoromethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3,4,5-trimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-vinylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-acetamidopyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-benzothienyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(1-benzothiophen-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(1-benzothiophen-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-bromo-3-chloropyridin-4-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-bromo-3-methylpyridin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-bromopyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-chloro-3-methylpyridin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-6-isopropylpyridin-3-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(5-chlorothien-2-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(5-bromothien-2-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-chloro-3-fluoropyridin-4-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,5-dibromopyridin-3-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,6-dichloropyridin-3-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,4-dimethoxypyrimidin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(3,5-dimethylisoxazol-4-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-ethoxy-6-(2-ethoxypyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-fluoro-3-methylpyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-fluoropyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-fluoropyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-formyl-2-furyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-formyl-thiophen-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(furan-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(furan-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(indol-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(isoquinolin-4-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-methylfuran-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(methoxypyrimidin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-methyl-1-benzothiophen-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-methyl-3-phenyl-4-isoxazolyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(3-methylpyridin-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-methylpyridin-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(5-methylpyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-methoxypyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(2-methoxypyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(pyridin-4-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(pyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(pyrimidin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(quinolin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(quinolin-8-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(thien-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-benzylamine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-methylbenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-methylbenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-methylbenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-methoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-methoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-methoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,5-dihydroxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-propoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-phenoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-[3,4-dichlorophenoxy]-benzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-[3,5-dichlorophenoxy]-benzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-bromobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-bromobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-bromobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-chlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-chlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-chlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-fluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-fluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,3-dichlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,4-dichlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,6-dichlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,4-dichlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,5-dichlorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,3-difluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,4-difluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,5-difluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,6-difluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,4-difluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,5-difluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,3,4-trifluorobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-trifluoromethylbenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-trifluoromethylbenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-trifluoromethylbenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-trifluoromethoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(5-trifluoromethoxybenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-nitrobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-nitrobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-nitrobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-cyanobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-cyanobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-dimethylaminobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-diethylaminobenzyl)-amine,

4-ethoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,4,5-trimethoxybenzyl)-amine,

4-isopropoxy-6-(4-acetamidophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-acetamidophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-acetylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-acetylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-acetylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(5-acetyl-2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-acetyl-3-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(5-acetyl-2-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-aminophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-aminomethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-benzyloxy-2-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-benzyloxy-3-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-bromophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-bromophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-bromo-2,5-dimethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-bromo-5-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-bromo-6-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-carboxy-5-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-carboxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-carboxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-carboxy-2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(5-carboxy-2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-carboxy-3-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-carboxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-5-formylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-5-hydroxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-chloro-4-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-4-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-chloro-2-fluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-chloro-5-methoxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-4-methylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-5-methylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-chloro-5-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-5-trifluoromethoxyphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-chloro-2-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-cyanophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-cyanophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-cyanophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,6-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3,4-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,6-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,4-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,3-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3,5-dichlorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3,5-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3,4-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,6-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,5-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,4-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,3-difluorophenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-[N,N-dimethylamino]phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-[N,N-dimethylaminomethyl]phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3,5-dimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3,4-dimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2,6-dimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2,6-dimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2,5-dimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2,4-dimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-ethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-ethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-ethoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-ethoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-ethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-fluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-fluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-fluoro-4-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-fluoro-3-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-fluoro-2-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-fluoro-5-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-fluoro-5-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-fluoro-2-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-formyl-5-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-formyl-2-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-formyl-5-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-hydroxy-4-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-hydroxymethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-hydroxymethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-hydroxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-hydroxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-iodophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-iodophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-isopropoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-isopropoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-methanesulfonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-methoxy-2-formylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-methoxycarbonylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3,4-methylenedioxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-methylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-(methylthio)phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-(methylthio)phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-morpholinophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-nitrophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-phenoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-(tert-butoxycarbonyl)phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3-(tert-butoxycarbonyl)phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-(tert-butoxycarbonyl)phenyl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(4-(tert-butoxycarbonylamino)-3-methoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-(tert-butylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-(2-thienyl)phenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-trifluoromethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2,4,6-trimethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3,4,5-trifluorophenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-trifluoromethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-trifluoromethylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3,4,5-trimethoxyphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-vinylphenyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-acetamidopyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-benzothienyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(1-benzothiophen-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(1-benzothiophen-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-bromo-3-chloropyridin-4-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-bromo-3-methylpyridin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-bromopyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-chloro-3-methylpyridin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-6-isopropylpyridin-3-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(5-chlorothien-2-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(5-bromothien-2-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-chloro-3-fluoropyridin-4-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,5-dibromopyridin-3-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,6-dichloropyridin-3-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,4-dimethoxypyrimidin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(3,5-dimethylisoxazol-4-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-pteridin-2-yl]-(4-fluoro-benzyl)-amine,

4-isopropoxy-6-(2-ethoxypyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-fluoro-3-methylpyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-fluoropyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-fluoropyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-formyl-2-furyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-formyl-thiophen-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(furan-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(furan-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(indol-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(isoquinolin-4-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-methylfuran-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(methoxypyrimidin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-methyl-1-benzothiophen-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-methyl-3-phenyl-4-isoxazolyl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(3-methylpyridin-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-methylpyridin-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(5-methylpyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-methoxypyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(2-methoxypyridin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(pyridin-4-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(pyridin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(pyrimidin-5-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(quinolin-3-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(quinolin-8-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(thien-2-yl)-pteridin-2-yl]-(4-fluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-benzylamine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-methylbenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-methylbenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-methylbenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-methoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-methoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-methoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,5-dihydroxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-propoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-phenoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-[3,4-dichlorophenoxy]-benzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-[3,5-dichlorophenoxy]-benzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-bromobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-bromobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-bromobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-chlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-chlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-chlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-fluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-fluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,3-dichlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,4-dichlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,6-dichlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,4-dichlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,5-dichlorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,3-difluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,4-difluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,5-difluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,6-difluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,4-difluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,5-difluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2,3,4-trifluorobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-trifluoromethylbenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-trifluoromethylbenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-trifluoromethylbenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-trifluoromethoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(5-trifluoromethoxybenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(2-nitrobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-nitrobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-nitrobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3-cyanobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-cyanobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-dimethylaminobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(4-diethylaminobenzyl)-amine,

4-isopropoxy-6-(4-fluorophenyl)-pteridin-2-yl]-(3,4,5-trimethoxybenzyl)-amine,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-chlorobenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-chlorobenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methylbenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methoxybenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methylbenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methylbenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methoxybenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methoxybenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-fluorobenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-fluorobenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-fluorobenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-chlorobenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-trifluoromethoxybenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-trifluoromethoxybenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-trifluoromethylbenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-trifluoromethylbenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-trifluoromethylbenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-bromobenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-bromobenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-bromobenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-iodobenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-hydroxybenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-4-methyl}-thien-2-ylbenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-morpholinobenzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-morpholinobenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-morpholinomethylbenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-(4-methylpiperazino)benzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-methylthiobenzene,

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-phenoxymethylbenzene,

4-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-(pyrrolidin-1-ylmethyl)benzene,

2-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-(pyrrolidin-1-ylmethyl)benzene, and

3-{[6-(4-fluorophenyl)-4-(2,2,2-trifluoroethylamino)-pteridin-2-ylamino]-methyl}-(pyrimidin-2-yl)benzene.

61. A pteridine derivative being 2-amino-4-isopropoxy-6-(4-fluorophenyl)-pteridine.

62. A method of treatment or prevention of an infection due to a virus from the Flaviridae family, consisting essentially of administering to a patient in need thereof a therapeutically effective amount of a pteridine derivative selected from the group consisting of 2-amino-4-ethoxy-6-(4-fluorophenyl)-pteridine and 2-amino-4-isopropoxy-6-(4-fluorophenyl)-pteridine.